Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-081612
Filing Date
2025-06-04
Accepted
2025-06-04 16:05:13
Documents
1
Period of Report
2025-06-02

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3275
  Complete submission text file 0000950170-25-081612.txt   4794
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Issuer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 3 FORBES ROAD LEXINGTON MA 02421
Business Address
Behner Peter (Reporting) CIK: 0001851420 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40908 | Film No.: 251023109